Key result
Intravenous vasodilators for acute heart failure fail to reduce long-term cardiovascular mortality.
Why the study?
Over the past decade, several trials have questioned the efficacy of vasodilator therapy in acute heart failure in the absence of uncontrolled hypertension.
Does vasodilator therapy reduce mortality and re-hospitalization in patients with acute heart failure?
Does vasodilator therapy reduce mortality and re-hospitalization in patients with acute heart failure?
Routine use of early vasodilator therapy in acute heart failure does not improve long-term mortality or re-hospitalization, though it may provide short-term symptomatic relief.
Does not support routine intravenous vasodilator use for long-term outcomes in acute heart failure; leaves open short-term symptomatic roles or targeted trials.
Over the past decade, several trials have questioned the efficacy of vasodilator therapy in acute heart failure (AHF) in the absence of uncontrolled hypertension. In this article, we provide a unique review of the most valuable four trials that present the role of vasodilator therapy in the management of patients with AHF. These four trials have evaluated the efficacy of different types of vasodilators such as nesiritide, ulatritide, and serelaxin in the setting of AHF. Also, we compared comprehensive vasodilator therapy versus standard therapy to see if there is any effect on mortality and re-hospitalization.
No takes yet. Share an insight, caveat, or question.
Batool et al. (2021) conducted a review in Acute Heart Failure. Vasodilator therapy vs. Placebo or standard care was evaluated on Long-term cardiovascular mortality (qualitative summary). Intravenous vasodilator therapy during hospitalization for acute heart failure failed to show a benefit for long-term cardiovascular mortality across multiple major clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: